Cargando…

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

Background. Numerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen. In addition to optimizing individual patient management, these baseline...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofstra, L. Marije, Sauvageot, Nicolas, Albert, Jan, Alexiev, Ivailo, Garcia, Federico, Struck, Daniel, Van de Vijver, David A. M. C., Åsjö, Birgitta, Beshkov, Danail, Coughlan, Suzie, Descamps, Diane, Griskevicius, Algirdas, Hamouda, Osamah, Horban, Andrzej, Van Kasteren, Marjo, Kolupajeva, Tatjana, Kostrikis, Leondios G., Liitsola, Kirsi, Linka, Marek, Mor, Orna, Nielsen, Claus, Otelea, Dan, Paraskevis, Dimitrios, Paredes, Roger, Poljak, Mario, Puchhammer-Stöckl, Elisabeth, Sönnerborg, Anders, Staneková, Danica, Stanojevic, Maja, Van Laethem, Kristel, Zazzi, Maurizio, Zidovec Lepej, Snjezana, Boucher, Charles A. B., Schmit, Jean-Claude, Wensing, Annemarie M. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741360/
https://www.ncbi.nlm.nih.gov/pubmed/26620652
http://dx.doi.org/10.1093/cid/civ963
_version_ 1782413978286161920
author Hofstra, L. Marije
Sauvageot, Nicolas
Albert, Jan
Alexiev, Ivailo
Garcia, Federico
Struck, Daniel
Van de Vijver, David A. M. C.
Åsjö, Birgitta
Beshkov, Danail
Coughlan, Suzie
Descamps, Diane
Griskevicius, Algirdas
Hamouda, Osamah
Horban, Andrzej
Van Kasteren, Marjo
Kolupajeva, Tatjana
Kostrikis, Leondios G.
Liitsola, Kirsi
Linka, Marek
Mor, Orna
Nielsen, Claus
Otelea, Dan
Paraskevis, Dimitrios
Paredes, Roger
Poljak, Mario
Puchhammer-Stöckl, Elisabeth
Sönnerborg, Anders
Staneková, Danica
Stanojevic, Maja
Van Laethem, Kristel
Zazzi, Maurizio
Zidovec Lepej, Snjezana
Boucher, Charles A. B.
Schmit, Jean-Claude
Wensing, Annemarie M. J.
author_facet Hofstra, L. Marije
Sauvageot, Nicolas
Albert, Jan
Alexiev, Ivailo
Garcia, Federico
Struck, Daniel
Van de Vijver, David A. M. C.
Åsjö, Birgitta
Beshkov, Danail
Coughlan, Suzie
Descamps, Diane
Griskevicius, Algirdas
Hamouda, Osamah
Horban, Andrzej
Van Kasteren, Marjo
Kolupajeva, Tatjana
Kostrikis, Leondios G.
Liitsola, Kirsi
Linka, Marek
Mor, Orna
Nielsen, Claus
Otelea, Dan
Paraskevis, Dimitrios
Paredes, Roger
Poljak, Mario
Puchhammer-Stöckl, Elisabeth
Sönnerborg, Anders
Staneková, Danica
Stanojevic, Maja
Van Laethem, Kristel
Zazzi, Maurizio
Zidovec Lepej, Snjezana
Boucher, Charles A. B.
Schmit, Jean-Claude
Wensing, Annemarie M. J.
author_sort Hofstra, L. Marije
collection PubMed
description Background. Numerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen. In addition to optimizing individual patient management, these baseline resistance data enable transmitted drug resistance (TDR) to be surveyed for public health purposes. The SPREAD program systematically collects data to gain insight into TDR occurring in Europe since 2001. Methods. Demographic, clinical, and virological data from 4140 antiretroviral-naive human immunodeficiency virus (HIV)–infected individuals from 26 countries who were newly diagnosed between 2008 and 2010 were analyzed. Evidence of TDR was defined using the WHO list for surveillance of drug resistance mutations. Prevalence of TDR was assessed over time by comparing the results to SPREAD data from 2002 to 2007. Baseline susceptibility to antiretroviral drugs was predicted using the Stanford HIVdb program version 7.0. Results. The overall prevalence of TDR did not change significantly over time and was 8.3% (95% confidence interval, 7.2%–9.5%) in 2008–2010. The most frequent indicators of TDR were nucleoside reverse transcriptase inhibitor (NRTI) mutations (4.5%), followed by nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.9%) and protease inhibitor mutations (2.0%). Baseline mutations were most predictive of reduced susceptibility to initial NNRTI-based regimens: 4.5% and 6.5% of patient isolates were predicted to have resistance to regimens containing efavirenz or rilpivirine, respectively, independent of current NRTI backbones. Conclusions. Although TDR was highest for NRTIs, the impact of baseline drug resistance patterns on susceptibility was largest for NNRTIs. The prevalence of TDR assessed by epidemiological surveys does not clearly indicate to what degree susceptibility to different drug classes is affected.
format Online
Article
Text
id pubmed-4741360
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-47413602016-02-05 Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe Hofstra, L. Marije Sauvageot, Nicolas Albert, Jan Alexiev, Ivailo Garcia, Federico Struck, Daniel Van de Vijver, David A. M. C. Åsjö, Birgitta Beshkov, Danail Coughlan, Suzie Descamps, Diane Griskevicius, Algirdas Hamouda, Osamah Horban, Andrzej Van Kasteren, Marjo Kolupajeva, Tatjana Kostrikis, Leondios G. Liitsola, Kirsi Linka, Marek Mor, Orna Nielsen, Claus Otelea, Dan Paraskevis, Dimitrios Paredes, Roger Poljak, Mario Puchhammer-Stöckl, Elisabeth Sönnerborg, Anders Staneková, Danica Stanojevic, Maja Van Laethem, Kristel Zazzi, Maurizio Zidovec Lepej, Snjezana Boucher, Charles A. B. Schmit, Jean-Claude Wensing, Annemarie M. J. Clin Infect Dis HIV/AIDS Background. Numerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen. In addition to optimizing individual patient management, these baseline resistance data enable transmitted drug resistance (TDR) to be surveyed for public health purposes. The SPREAD program systematically collects data to gain insight into TDR occurring in Europe since 2001. Methods. Demographic, clinical, and virological data from 4140 antiretroviral-naive human immunodeficiency virus (HIV)–infected individuals from 26 countries who were newly diagnosed between 2008 and 2010 were analyzed. Evidence of TDR was defined using the WHO list for surveillance of drug resistance mutations. Prevalence of TDR was assessed over time by comparing the results to SPREAD data from 2002 to 2007. Baseline susceptibility to antiretroviral drugs was predicted using the Stanford HIVdb program version 7.0. Results. The overall prevalence of TDR did not change significantly over time and was 8.3% (95% confidence interval, 7.2%–9.5%) in 2008–2010. The most frequent indicators of TDR were nucleoside reverse transcriptase inhibitor (NRTI) mutations (4.5%), followed by nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.9%) and protease inhibitor mutations (2.0%). Baseline mutations were most predictive of reduced susceptibility to initial NNRTI-based regimens: 4.5% and 6.5% of patient isolates were predicted to have resistance to regimens containing efavirenz or rilpivirine, respectively, independent of current NRTI backbones. Conclusions. Although TDR was highest for NRTIs, the impact of baseline drug resistance patterns on susceptibility was largest for NNRTIs. The prevalence of TDR assessed by epidemiological surveys does not clearly indicate to what degree susceptibility to different drug classes is affected. Oxford University Press 2016-03-01 2015-11-29 /pmc/articles/PMC4741360/ /pubmed/26620652 http://dx.doi.org/10.1093/cid/civ963 Text en © The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, contact journals.permissions@oup.com.
spellingShingle HIV/AIDS
Hofstra, L. Marije
Sauvageot, Nicolas
Albert, Jan
Alexiev, Ivailo
Garcia, Federico
Struck, Daniel
Van de Vijver, David A. M. C.
Åsjö, Birgitta
Beshkov, Danail
Coughlan, Suzie
Descamps, Diane
Griskevicius, Algirdas
Hamouda, Osamah
Horban, Andrzej
Van Kasteren, Marjo
Kolupajeva, Tatjana
Kostrikis, Leondios G.
Liitsola, Kirsi
Linka, Marek
Mor, Orna
Nielsen, Claus
Otelea, Dan
Paraskevis, Dimitrios
Paredes, Roger
Poljak, Mario
Puchhammer-Stöckl, Elisabeth
Sönnerborg, Anders
Staneková, Danica
Stanojevic, Maja
Van Laethem, Kristel
Zazzi, Maurizio
Zidovec Lepej, Snjezana
Boucher, Charles A. B.
Schmit, Jean-Claude
Wensing, Annemarie M. J.
Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe
title Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe
title_full Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe
title_fullStr Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe
title_full_unstemmed Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe
title_short Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe
title_sort transmission of hiv drug resistance and the predicted effect on current first-line regimens in europe
topic HIV/AIDS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741360/
https://www.ncbi.nlm.nih.gov/pubmed/26620652
http://dx.doi.org/10.1093/cid/civ963
work_keys_str_mv AT hofstralmarije transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT sauvageotnicolas transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT albertjan transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT alexievivailo transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT garciafederico transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT struckdaniel transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT vandevijverdavidamc transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT asjobirgitta transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT beshkovdanail transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT coughlansuzie transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT descampsdiane transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT griskeviciusalgirdas transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT hamoudaosamah transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT horbanandrzej transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT vankasterenmarjo transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT kolupajevatatjana transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT kostrikisleondiosg transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT liitsolakirsi transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT linkamarek transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT mororna transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT nielsenclaus transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT oteleadan transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT paraskevisdimitrios transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT paredesroger transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT poljakmario transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT puchhammerstocklelisabeth transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT sonnerborganders transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT stanekovadanica transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT stanojevicmaja transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT vanlaethemkristel transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT zazzimaurizio transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT zidoveclepejsnjezana transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT bouchercharlesab transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT schmitjeanclaude transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope
AT wensingannemariemj transmissionofhivdrugresistanceandthepredictedeffectoncurrentfirstlineregimensineurope